Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
57894-0501-01 57894-0501 Amivantamab-vmjw Rybrevant 350.0 mg/1 Immunotherapy Monoclonal Antibody EGFR, MET Intravenous May 21, 2021 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Apr 15, 2023 In Use
00480-1241-28 00480-1241 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 8, 2023 In Use
83077-0100-02 83077-0100 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Monoclonal Antibody HER2, HER3 Intravenous Dec 4, 2024 In Use
00007-3261-01 00007-3261 Tositumomab, Iodine I-131 Bexxar Dosimetric Immunotherapy Radioimmunotherapy CD20 Jul 15, 2009 Feb 13, 2014 No Longer Used
68152-0104-04 68152-0104 Ibritumomab Tiuxetan Zevalin Immunotherapy Radioimmunotherapy CD20 Feb 19, 2002 Dec 3, 2011 No Longer Used
60505-4499-02 60505-4499 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 11, 2026 In Use
00378-1935-28 00378-1935 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 7, 2023 In Use
16729-0696-06 16729-0696 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 26, 2026 In Use
60505-4497-02 60505-4497 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 11, 2026 In Use
67457-0847-44 67457-0847 Trastuzumab OGIVRI 420.0 mg/ 20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov 29, 2019 Apr 30, 2027 In Use
82293-0009-10 82293-0009 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 6, 2026 In Use
31722-0770-21 31722-0770 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
31722-0772-32 31722-0772 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
31722-0773-32 31722-0773 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
00004-0357-30 00004-0357 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Mar 29, 2011 Jun 30, 2024 No Longer Used
31722-0773-21 31722-0773 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
16729-0697-06 16729-0697 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Apr 8, 2026 In Use
70710-1035-01 70710-1035 LENALIDOMIDE LENALIDOMIDE 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 12, 2022 In Use
57894-0450-01 57894-0450 Teclistamab-cqyv TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
55513-0160-21 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Apr 30, 2026 In Use
59572-0503-21 59572-0503 Pomalidomide Pomalyst 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 18, 2013 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec 18, 2014 In Use
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Dec 19, 2025 In Use
58468-0357-03 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov 30, 2009 In Use

Found 12393 results — Export these results